 Avalon GloboCare Corp NASDAQ:AVCO has received a notice of allowance from the US Patent and Trademark Office USPTO related to its QTY fusion water-soluble receptor protein platform. The companys QTY code is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development, the company said. 